Home / Medicine / Risperdal

Risperdal

Marketed in 46 countries across the Americas, Europe, Asia, Africa, and Oceania, Risperdal is a globally distributed brand of risperidone, classified as an antipsychotic within the broader psycholeptic category. For an international reader trying to identify the medication abroad — whether as a traveller carrying a prescription, an expatriate adjusting to a new healthcare system, or a family member helping a relative — the wide footprint usually means an equivalent product is reachable, though not always under the same name.

Risperdal is prescribed in the management of several psychiatric and neurodevelopmental conditions, including schizophrenia, bipolar disorder, behavioural symptoms in dementia, delirium, certain presentations associated with intellectual disability, and conduct disorder. The structured indication block further down this page reflects the registered uses recognised across the markets where Risperdal is authorised, and these can vary somewhat between national regulators.

Because risperidone is so widely registered, the same molecule frequently turns up under different commercial names across borders. Markets where Risperdal itself is registered include Brazil, China, Canada, France, and Australia, but local packaging, prescription pathways, and the availability of generic risperidone differ considerably from one country to another. A pharmacist in the destination country can confirm whether a locally-stocked risperidone product corresponds to what the patient has been taking.

Other medications in the antipsychotic class are also distributed globally under various molecules and brand names, and a clinician familiar with the patient's history is best placed to assess whether any substitution is appropriate. Continuity of psychiatric medication is rarely a casual decision — for anyone considering a change while abroad, that conversation should sit with a treating healthcare provider rather than with a pharmacy counter.

Countries
Argentina Australia Austria Bangladesh Belgium Brazil Canada Chile China Colombia Czech Republic Denmark Egypt Finland France Germany Greece Hong Kong Hungary Iceland India Indonesia Ireland Israel Italy Japan Lebanon Malaysia Malta Netherlands New Zealand Norway Oman Peru Philippines Portugal Singapore South Africa Switzerland Taiwan Thailand Tunisia Turkey United Kingdom USA Vietnam
Diseases
Dementia Schizophrenia Bipolar disorder Delirium Intellectual disability Conduct disorder
Ingredients
Risperidone
Drug Actions
Sedative Antipsychotic Psychoanaleptics Psycholeptics Antiemetic Hypothermic

Drugs with the same active ingredients

Dozic Dropicine Edalen Restelea Riatul Ribastamin duo Risper Risperdal consta Risperidona cevallos Risperidona dosa Risperidona fabra Risperin Rispex Rivosten Roxodyn Sequinan Acris combi Actonel ec combi Apo-risperidone Ozidal

Date of revision of the text

09/2017

Marketing authorisation holder

Janssen-Cilag Ltd

50-100 Holmers Farm Way

High Wycombe

Buckinghamshire

HP12 4EG

UK

Special precautions for storage

Do not store above 30°C.

Blister packs: Store in the original package in order to protect from light.

Nature and contents of container

RISPERDAL film-coated tablets are packaged in PVC/LDPE/PVDC/aluminium foil blisters and HDPE bottles with PP screw cap.

RISPERDAL film-coated tablets are available in the following pack sizes:

● 0.5 mg: blister packs containing 20 or 50 tablets and bottles containing 500 tablets

● 1 mg: blister packs containing 6, 20, 50, 60, or 100 tablets and bottles containing 500 tablets

● 2 mg: blister packs containing 10, 20, 50, 60, or 100 tablets and bottles containing 500 tablets

● 3 mg: blister packs containing 20, 50, 60, or 100 tablets

● 4 mg: blister packs containing 10, 20, 30, 50, 60, or 100 tablets

● 6 mg: blister packs containing 28, 30, or 60 tablets.

Not all pack sizes may be marketed.

Marketing authorisation number(s)

PL 00242/0347 (0.5 mg)

PL 00242/0186 (1 mg)

PL 00242/0187 (2 mg)

PL 00242/0188 (3 mg)

PL 00242/0189 (4 mg)

PL 00242/0317 (6 mg)

Special precautions for disposal and other handling

No special requirements for disposal.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Date of first authorisation/renewal of the authorisation

Date of first authorisation:

03 June 2000 (0.5 mg film-coated tablets)

08 December 1992 (1/2/3/4 mg film-coated tablets)

15 July 1997 (6 mg film-coated tablets)

Date of latest renewal:

30 April 2017

Frequently asked questions

What conditions does Risperdal treat?

Risperdal is prescribed in the management of several psychiatric and neurodevelopmental conditions, including schizophrenia, bipolar disorder, dementia-related symptoms, delirium, certain presentations of intellectual disability, and conduct disorder. As an antipsychotic, it sits within a class of medications used in psychiatry and neurology across very different patient profiles. The structured indication section below this introduction lists each registered use as recognised in the markets where Risperdal is sold.

Which active substance is in Risperdal?

Risperdal contains risperidone, classified as an antipsychotic and within the broader psycholeptic category. Risperidone is the same molecule whether sold as Risperdal or as a generic, and it circulates internationally under a number of different brand names — particularly in markets where the original patent has expired and multiple manufacturers produce risperidone-containing products in parallel.

In how many countries is Risperdal available?

Risperdal is registered in 46 countries spanning North and South America, Europe, Asia, Africa, and Oceania. Examples include Brazil, China, Canada, Egypt, France, and Australia. If your country is not represented in the structured list further down this page, a local pharmacist can usually confirm whether risperidone is available locally — either under a different brand name or as a generic preparation.

Are there other medications with the same active ingredient as Risperdal?

Risperidone is marketed under several brand names worldwide, especially in markets where generic manufacturers have entered after patent expiry. Other medications within the broader antipsychotic class also exist, although they are not freely interchangeable — molecules within the class differ meaningfully in profile and clinical positioning. To identify a local risperidone-containing product, search the active ingredient on Pill2Trip or ask a pharmacist in your country.

Should I consult a doctor before taking Risperdal?

Yes. Risperdal is a prescription medication, and antipsychotic therapy is calibrated carefully to a patient's full psychiatric history, concurrent medications, and individual circumstances. This is particularly relevant for travellers and people relocating between countries, since prescription requirements, available brands, and generic formulations can differ across regulatory regimes. Any decision to start, stop, switch, or substitute risperidone should involve a healthcare provider who knows the patient.

Risperdal

Available in 46 countries